Davies G J, Kobrin I, Caspi A, Reisin L H, de Albuquerque D C, Armagnijan D, Coelho O R, Schneeweiss A
Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
Am Heart J. 1997 Aug;134(2 Pt 1):220-8. doi: 10.1016/s0002-8703(97)70128-5.
This study compared the efficacy, safety, and tolerability of mibefradil to sustained-release diltiazem in patients with chronic stable angina pectoris. At week 12, statistically equivalent mean increases in exercise tolerance test (ETT) duration of > 1 minute were observed in both groups. Similar improvements in time to onset of angina and time to persistent 1 mm ST-segment depression were also observed with both drugs. Large reductions in heart rate, blood pressure, and rate-pressure product were observed at each stage of the ETT among patients treated with mibefradil. Each drug was associated with at least a 70% reduction from baseline in anginal frequency and nitroglycerin consumption. Patients maintained on mibefradil during the withdrawal period had significant increases in all three ETT variables at week 16 compared with placebo. The effectiveness of mibefradil is comparable with sustained-release diltiazem in treating chronic stable angina pectoris, although mibefradil provides greater reductions in heart rate and cardiac workload.
本研究比较了米贝拉地尔与缓释地尔硫䓬对慢性稳定型心绞痛患者的疗效、安全性和耐受性。在第12周时，两组患者运动耐量试验（ETT）持续时间的平均增加在统计学上相当，均超过1分钟。两种药物在心绞痛发作时间和持续性ST段压低1毫米的时间方面也有类似改善。在用米贝拉地尔治疗的患者中，在ETT的每个阶段都观察到心率、血压和心率-血压乘积大幅降低。每种药物都使心绞痛发作频率和硝酸甘油消耗量比基线至少降低70%。与安慰剂相比，在撤药期继续服用米贝拉地尔的患者在第16周时所有三个ETT变量均显著增加。米贝拉地尔在治疗慢性稳定型心绞痛方面的有效性与缓释地尔硫䓬相当，尽管米贝拉地尔能更大程度地降低心率和心脏负荷。
